August
2024
Preliminary
Pricing Supplement No. 3,333
Registration
Statement Nos. 333-275587; 333-275587-01
Dated August
2, 2024
Filed pursuant
to Rule 424(b)(2)
Morgan
Stanley Finance LLC
Structured
Investments
Opportunities in U.S. Equities
Market
Linked Securities—Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities
Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
Fully and Unconditionally
Guaranteed by Morgan Stanley
§
Linked to the common stock of Eli Lilly and Company (the “underlying stock”)
§
The securities offered are unsecured obligations of Morgan Stanley Finance LLC (“MSFL”) and are fully and unconditionally
guaranteed by Morgan Stanley. Unlike ordinary debt securities, the securities do not pay interest, do not guarantee the repayment of principal
and are subject to potential automatic call prior to the maturity date upon the terms described below. The securities have the terms described
in the accompanying product supplement for principal at risk securities and prospectus, as supplemented or modified by this document.
§
Automatic Call. The securities will be automatically called if the stock closing price on the call date is greater than or equal
to the starting price for a call payment equal to the face amount plus the call premium of at least 18.40% of the face amount
(to be determined on the pricing date). No further payments will be made on the securities once they have been called.
§
Maturity Payment Amount. If the securities are not automatically called prior to maturity, you will receive at maturity a cash
payment per security as follows:
§
If the ending price of the underlying stock is greater than the starting price, you will receive a maturity payment amount equal
to the face amount plus a positive return equal to 150% of the percentage increase in the price of the underlying stock from the
starting price.
§
If the ending price of the underlying stock is equal to or less than the starting price, but greater than or equal to 75%
of the starting price, which we refer to as the threshold price, you will receive a maturity payment amount of $1,000 per $1,000 security.
§
If the ending price of the underlying stock is less than the threshold price, you will have full downside exposure to the decrease
in the price of the underlying stock from its starting price, and you will lose more than 25%, and possibly all, of your initial investment.
§
The maturity payment amount may be significantly less than the face amount, and you could lose your entire investment.
§
The securities are for investors who are willing to risk their principal and forgo current income in exchange for the possibility of receiving
a call payment greater than the face amount if the stock closing price is greater than or equal to the starting price on the call
date or maturity payment amount greater than the face amount if the ending price of the underlying stock is greater than the starting
price on the calculation day.
§
If the securities are automatically called prior to maturity, investors will not participate in any appreciation of the underlying stock.
§
The securities are notes issued as part of MSFL’s Series A Global Medium-Term Notes program
§
All payments are subject to our credit risk. If we default on our obligations, you could lose some or all of your investment
§
These securities are not secured obligations and you will not have any security interest in, or otherwise have any access to, the underlying
stock. |
The
current estimated value of the securities is approximately $961.40 per security, or within $30.00 of that estimate. The estimated value
of the securities is determined using our own pricing and valuation models, market inputs and assumptions relating to the underlying
stock, instruments based on the underlying stock, volatility and other factors including current and expected interest rates, as well
as an interest rate related to our secondary market credit spread, which is the implied interest rate at which our conventional fixed
rate debt trades in the secondary market. See “Estimated Value of the Securities” on page 4.
The
securities have complex features and investing in the securities involves risks not associated with an investment in ordinary debt securities.
See “Risk Factors” beginning on page 10. All payments on the securities are subject to our credit risk.
The
Securities and Exchange Commission and state securities regulators have not approved or disapproved these securities, or determined if
this document or the accompanying product supplement and prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.
The
securities are not deposits or savings accounts and are not insured by the Federal Deposit Insurance Corporation or any other governmental
agency or instrumentality, nor are they obligations of, or guaranteed by, a bank.
You
should read this document together with the related product supplement for principal at risk securities and prospectus, each of which
can be accessed via the hyperlinks below. When you read the accompanying product supplement, please note that all references in such
supplement to the prospectus dated November 16, 2023, or to any sections therein, should refer instead to the accompanying prospectus
dated April 12, 2024 or to the corresponding sections of such prospectus, as applicable. Please also see “Additional Information
About the Securities” at the end of this document.
As
used in this document, “we,” “us” and “our” refer to Morgan Stanley or MSFL, or Morgan Stanley and
MSFL collectively, as the context requires.
Commissions
and offering price: |
Price
to public |
Agent’s
commissions(1)(2) |
Proceeds
to us(3) |
Per
security |
$1,000 |
$25.75 |
$974.25 |
Total |
$ |
$ |
$ |
| (1) | Wells
Fargo Securities, LLC, an agent for this offering, will receive a commission of up to $25.75
for each security it sells. Dealers, including Wells Fargo Advisors (“WFA”),
may receive a selling concession of up to $20.00 per security, and WFA may receive a distribution
expense fee of $0.75 for each security sold by WFA. See “Supplemental information concerning
plan of distribution; conflicts of interest.” |
| (2) | In
respect of certain securities sold in this offering, we may pay a fee of up to $2.50 per
security to selected securities dealers in consideration for marketing and other services
in connection with the distribution of the securities to other securities dealers. |
| (3) | See
“Use of Proceeds and Hedging” in the accompanying product supplement. |
Product
Supplement for Principal at Risk Securities dated November 16, 2023 Prospectus
dated April 12, 2024
Morgan Stanley |
Wells Fargo Securities |
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
Issuer: |
Morgan Stanley Finance LLC |
Guarantor: |
Morgan Stanley |
Maturity
date: |
August 19, 2027†, subject to postponement if the calculation day is postponed |
Underlying
stock: |
The common stock of Eli Lilly and Company (the “Underlying company”) (NYSE symbol: LLY) |
Automatic
call: |
If, on the call date, the stock closing price is greater than or
equal to the starting price, the securities will be automatically called for the call payment on the call settlement date.
The securities will not be automatically called on the call settlement
date if the stock closing price is less than the starting price on the call date.
If the securities are automatically called, the positive return
on the securities will be limited to the call premium, even if the stock closing price on the call date significantly exceeds the starting
price. If the securities are automatically called, you will not participate in any appreciation of the underlying stock. |
Call
payment: |
The call payment will be an amount in cash per face amount of at least
$1,184, which corresponds to a call premium of at least 18.40% of the face amount. The actual call payment and call premium will be determined
on the pricing date.
No further payments will be made on the securities once they have been
called. |
Call
date: |
August 21, 2025†* |
Call
settlement date: |
Three business days after the call date.* |
Maturity payment amount: |
If the securities are not automatically called prior to maturity, you
will be entitled to receive on the maturity date a cash payment per security as follows:
§ if
the ending price of the underlying stock is greater than the starting price:
$1,000 + ($1,000 × stock return × participation
rate)
§ if
the ending price of the underlying stock is equal to or less than the starting price but greater than or equal to the threshold
price:
$1,000
§ if
the ending price of the underlying stock is less than the threshold price:
$1,000 + ($1,000 ×
stock return)
Under these circumstances, you will lose more than 25%,
and possibly all, of your investment. |
Participation
rate: |
150% |
Stock
closing price: |
With respect to the underlying stock, stock closing price, closing price and adjustment factor have the meanings set forth under “General Terms of the Securities—Certain Terms for Securities Linked to an Underlying Stock—Certain Definitions” in the accompanying product supplement for principal at risk securities. |
Starting
price: |
$ , which is the stock closing price on the pricing date |
Ending
price: |
The stock closing price on the calculation day |
Threshold
price: |
$ , which is equal to 75% of the starting price |
Calculation
day: |
August 16, 2027**†, subject to postponement for non-trading days and certain market disruption events. |
Stock
return: |
(ending price – starting price) / (starting price) |
Face
amount: |
$1,000 per security. References in this document to a “security” are to a security with a face amount of $1,000. |
Pricing
date: |
August 16, 2024*† |
Original
issue date: |
August 21, 2024*† (3 business days after the pricing date) |
CUSIP
/ ISIN: |
61776RCH5 / US61776RCH57 |
Listing: |
The securities will not be listed on any securities exchange. |
Agents: |
Morgan Stanley & Co. LLC (“MS & Co.”), an affiliate of MSFL and a wholly owned subsidiary of |
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
|
Morgan Stanley, and Wells Fargo Securities, LLC (“WFS”). See “Additional Information About the Securities—Supplemental information regarding plan of distribution; conflicts of interest.” |
†To the extent we make any
change to the pricing date or original issue date, the call date, calculation day and maturity date may also be changed in our discretion
to ensure that the term of the securities remains the same.
* Subject to postponement pursuant
to “General Terms of the Securities—Consequences of a Market Disruption Event; Postponement of a Calculation Day”
in the accompanying product supplement for principal at risk securities. |
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
Estimated
Value of the Securities |
The face amount of each security is $1,000. This price includes costs
associated with issuing, selling, structuring and hedging the securities, which are borne by you, and, consequently, the estimated value
of the securities on the pricing date will be less than $1,000 per security. We estimate that the value of each security on the pricing
date will be approximately $961.40, or within $30.00 of that estimate. Our estimate of the value of the securities as determined on the
pricing date will be set forth in the final pricing supplement.
What goes into the estimated value on the pricing date?
In valuing the securities on the pricing date, we take into account
that the securities comprise both a debt component and a performance-based component linked to the underlying stock. The estimated value
of the securities is determined using our own pricing and valuation models, market inputs and assumptions relating to the underlying stock,
instruments based on the underlying stock, volatility and other factors including current and expected interest rates, as well as an interest
rate related to our secondary market credit spread, which is the implied interest rate at which our conventional fixed rate debt trades
in the secondary market.
What determines the economic terms of the securities?
In determining the economic terms of the securities, including the
call payment amount and the threshold price, we use an internal funding rate which is likely to be lower than our secondary market credit
spreads and therefore advantageous to us. If the issuing, selling, structuring and hedging costs borne by you were lower or if the internal
funding rate were higher, one or more of the economic terms of the securities would be more favorable to you.
What is the relationship between the estimated value on the pricing
date and the secondary market price of the securities?
The price at which MS & Co. purchases the securities in the secondary
market, absent changes in market conditions, including those related to the underlying stock, may vary from, and be lower than, the estimated
value on the pricing date, because the secondary market price takes into account our secondary market credit spread as well as the bid-offer
spread that MS & Co. would charge in a secondary market transaction of this type and other factors. However, because the costs associated
with issuing, selling, structuring and hedging the securities are not fully deducted upon issuance, for a period of up to 3 months following
the issue date, to the extent that MS & Co. may buy or sell the securities in the secondary market, absent changes in market conditions,
including those related to the underlying stock, and to our secondary market credit spreads, it would do so based on values higher than
the estimated value. We expect that those higher values will also be reflected in your brokerage account statements.
MS & Co. may, but is not obligated to, make a market in the securities
and, if it once chooses to make a market, may cease doing so at any time.
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
The Principal at Risk Securities Linked to the
Common Stock of Eli Lilly and Company due August 19, 2027 (the “securities”) may be appropriate for investors who:
| § | believe that the stock closing price will be
greater than or equal to the starting price on the call date; |
| § | seek the potential for a fixed return if the
underlying stock has appreciated at all as of the call date in lieu of 150% leveraged participation in any potential appreciation of the
underlying stock; |
| § | if the securities are not automatically called
prior to maturity, seek exposure to 150% of the positive performance of the underlying stock if the ending price of the underlying stock
is greater than the starting price; |
| § | understand that if the stock closing price is
less than the starting price on the call date and the ending price of the underlying stock is less than the starting price
on the calculation day, they will not receive any positive return on their investment in the securities, and that if the stock closing
price on the calculation day has declined by more than 25% from the starting price, they will lose more than 25%, and possibly all, of
the face amount of their securities at maturity; |
| § | understand that the term of the securities may
be as short as approximately one year, and that if the securities are automatically called, no further payments will be made on the securities
once they have been called; |
| § | understand and are willing to accept the full
downside risks of the underlying stock; |
| § | are willing to forgo interest payments on the
securities and dividends on the underlying stock; and |
| § | are willing to hold the securities until maturity. |
The securities are not designed for, and may not
be an appropriate investment for, investors who:
| § | seek a liquid investment or are unable or unwilling
to hold the securities to maturity; |
| § | require full payment of the face amount of the
securities at maturity; |
| § | believe that the stock closing price will be
less than the starting price on the call date or the calculation day; |
| § | seek a security with a fixed term; |
| § | are unwilling to accept the risk that, if the
stock closing price is less than the starting price on the call date and, if the securities are not automatically called prior to maturity,
the calculation day, they will not receive any positive return on their investment in the securities; |
| § | are unwilling to accept the risk that, if the
securities are not automatically called prior to maturity, the price of the underlying stock on the calculation day may decline by more
than 25% from the starting price to the ending price, in which case they will lose more than 25%, and possibly all, of the face amount
of their securities at maturity; |
| § | are unwilling to accept the risk of exposure
to the underlying stock; |
| § | are unwilling to accept our credit risk; or |
| § | prefer the lower risk of fixed income investments
with comparable maturities issued by companies with comparable credit ratings. |
The considerations identified above are not
exhaustive. Whether or not the securities are an appropriate investment for you will depend on your individual circumstances, and you
should reach an investment decision only after you and your investment, legal, tax, accounting and other advisors have carefully considered
the appropriateness of an investment in the securities in light of your particular circumstances. You should also review carefully the
“Risk Factors” herein and in the accompanying product supplement for risks related to an investment in the securities. For
more information about the underlying stock, please see the section titled “Eli Lilly and Company Overview” below.
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
Determining Timing and Amount of Payment on the Securities |
The timing and amount of the payment you will receive will be determined
as follows:
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
Hypothetical Payout Profile |
The hypothetical payout profile
below illustrates the call payment or maturity payment amount on the securities, as applicable, for a range of hypothetical performances
of the underlying stock from the starting price to the closing price on the call date or the calculation day, as applicable.
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
Scenario Analysis and Examples of Hypothetical Payments on the Securities |
The following scenario analysis
and examples are provided for illustrative purposes only and are hypothetical. Whether the securities are automatically called prior to
maturity will be determined by reference to the stock closing price on the call date, and the maturity payment amount will be determined
by reference to the stock closing price on the calculation day. The actual call payment, starting price and threshold price will be determined
on the pricing date. Some numbers appearing in the examples below have been rounded for ease of analysis. All payments on the securities
are subject to our credit risk. The below examples are based on the following terms*:
Investment term: |
Approximately 3 years |
Hypothetical call payment: |
The hypothetical call payment will
be an amount in cash per face amount (corresponding to a return of approximately 18.40% of the face amount), as follows:
·
Call date: $1,184
No further payments will be
made on the securities once they have been called. |
Hypothetical starting price: |
$100.00 |
Hypothetical threshold price: |
$75.00, which is 75% of the hypothetical starting price |
Participation rate: |
150% |
* The hypothetical starting price of $100.00 for the underlying
stock has been chosen for illustrative purposes only and does not represent the actual starting price of the underlying stock. The actual
starting price and threshold price will be determined on the pricing date and will be set forth under “Terms” above. For historical
data regarding the actual closing prices of the underlying stock, see the historical information set forth herein.
Automatic Call:
Example 1 — The securities are automatically
called following the call date.
Date |
Stock Closing Price |
Payment (per Security) |
Call date |
$125.00 (greater than or equal to the starting price) |
$1,184 |
In this example, on the call date, the stock closing price is greater
than or equal to the starting price. Therefore, the securities are automatically called on the call settlement date. Investors will
receive a payment of $1,184 per security on the call settlement date. No further payments will be made on the securities once they have
been called, and investors do not participate in the appreciation in the underlying stock.
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
How to calculate the payment investors will receive at maturity:
In the following examples, the stock closing price
is less than the starting price on the call date, and, consequently, the securities are not automatically called prior to maturity.
|
Stock Closing Price |
Maturity Payment Amount (per Security) |
Example 1 |
$110.00 (greater than the starting price) |
$1,000 + ($1,000 × stock return × participation rate) = $1,000 + ($1,000 × 10% × 150%) = $1,150 |
Example 2 |
$95.00 (less than the starting price but greater than or equal to the threshold price) |
$1,000 |
Example 3 |
$30.00 (less than the threshold price) |
$1,000 + ($1,000 × stock return) = $1,000 + ($1,000 × -70%)= $300 |
In example 1, the ending price of the underlying
stock is greater than the starting price. Therefore, investors receive at maturity the face amount plus a return reflecting
150% of the appreciation of the underlying stock. Investors receive $1,150 per security at maturity.
In example 2, the ending price is less than
the starting price but greater than or equal to the threshold price. Therefore, investors receive a maturity payment amount equal
to the face amount of $1,000 per security, representing a 0% return over the 3-year term of the securities.
In example 3, the ending price of the underlying
stock is less than the threshold price. Therefore, investors are fully exposed to the negative performance of the underlying stock
and will receive a maturity payment amount that is less than the face amount of the securities. The maturity payment amount is $300 per
security, representing a loss of 70% on your investment over the 3-year term of the securities.
If the securities are not automatically called
prior to maturity and the ending price of the underlying stock is less than the threshold price on the calculation day, you will be fully
exposed to the decline in the stock closing price. You may lose more than 25%, and possibly all, of your investment.
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
This section describes the material risks relating to the securities.
For further discussion of these and other risks, you should read the section entitled “Risk Factors” in the accompanying product
supplement for principal at risk securities and prospectus. We also urge you to consult your investment, legal, tax, accounting and other
advisers in connection with your investment in the securities.
Risks Relating to an Investment in the Securities
| § | The securities do not pay interest or guarantee the return
of the face amount of your securities at maturity. The terms of the securities differ from those of ordinary debt securities in that
they do not pay interest or guarantee the return of the face amount of your securities at maturity. If the securities have not been automatically
called and if the ending price of the underlying stock is less than the threshold price, you will lose more than 25%, and possibly all,
of your investment. |
| § | If the securities are automatically
called prior to maturity, the appreciation potential of the securities is limited by the fixed call payment specified for the call date.
If the stock closing price is greater than or equal to the starting price on the call date, the securities will be automatically
called. In this scenario, the appreciation potential of the securities is limited to the fixed call payment specified on the call date,
and no further payments will be made on the securities once they have been called. In addition, if the securities are automatically called
prior to maturity, you will not participate in any appreciation of the underlying stock, which could be significant. Moreover, the fixed
call payment may be less than the maturity payment amount you would receive for the same price of appreciation of the underlying stock
had the securities not been automatically called and instead remained outstanding until maturity. |
| § | The
market price will be influenced by many unpredictable factors. Several factors, many
of which are beyond our control, will influence the value of the securities in the secondary
market and the price at which MS & Co. may be willing to purchase or sell the securities
in the secondary market. We expect that generally the price of interest rates available in
the market and the value of the underlying stock on any day, including in relation to the
starting price and threshold price, will affect the value of the securities more than any
other factors. Other factors that may influence the value of the securities include: |
| o | the trading price and volatility (frequency and magnitude of changes in value) of the underlying stock, |
| o | geopolitical conditions and economic, financial, political, regulatory or judicial events that affect the underlying stock or securities
markets generally and which may affect the price of the underlying stock |
| o | dividend rates on the underlying stock, |
| o | the time remaining until the securities mature, |
| o | interest and yield rates in the market, |
| o | the availability of comparable instruments, |
| o | the occurrence of certain events affecting the underlying stock that may or may not require an adjustment to the adjustment factor,
and |
| o | any actual or anticipated changes in our credit ratings or credit spreads. |
Generally, the longer the time remaining
to maturity, the more the market price of the securities will be affected by the other factors described above. Some or all of these
factors will influence the price that you will receive if you sell your securities prior to maturity. For example, you may have to sell
your securities at a substantial discount from the face amount of $1,000 per security if the price of the underlying stock at the time
of sale is near or below the threshold price or if market interest rates rise.
You cannot predict the future performance
of the underlying stock based on its historical performance. If the securities are not automatically called prior to maturity and the
ending price of the underlying stock is less than the threshold price, you will be exposed to any decline in the stock closing price
in excess of 10%. See “Eli Lilly and Company Overview” below.
| § | The securities are subject to our credit risk, and any
actual or anticipated changes to our credit ratings or credit spreads may adversely affect the market value of the securities. You
are dependent on our ability to pay all amounts due on the securities upon an automatic call or at maturity, and therefore you are subject
to our credit risk. If we default on our obligations under the securities, your investment would be at risk and you could lose some or
all of your investment. As a result, the market value of the securities prior to maturity will be affected by changes in the market’s
view of our creditworthiness. Any actual or anticipated decline in our credit ratings or increase in the credit spreads charged by the
market for taking our credit risk is likely to adversely affect the market value of the securities. |
| § | As a finance subsidiary, MSFL has no independent operations
and will have no independent assets. As a finance subsidiary, MSFL has no independent operations beyond the issuance and administration
of its securities and will have no independent assets available for distributions to holders of MSFL securities if they make claims in
respect of such securities in a |
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
bankruptcy, resolution or similar proceeding.
Accordingly, any recoveries by such holders will be limited to those available under the related guarantee by Morgan Stanley and that
guarantee will rank pari passu with all other unsecured, unsubordinated obligations of Morgan Stanley. Holders will have recourse
only to a single claim against Morgan Stanley and its assets under the guarantee. Holders of securities issued by MSFL should accordingly
assume that in any such proceedings they would not have any priority over and should be treated pari passu with the claims of other
unsecured, unsubordinated creditors of Morgan Stanley, including holders of Morgan Stanley-issued securities.
| § | Investing in the securities is not equivalent to investing
in the underlying stock. Investing in the securities is not equivalent to investing in the underlying stock. Investors in the securities
will not have voting rights or rights to receive dividends or other distributions or any other rights with respect to the underlying stock.
As a result, any return on the securities will not reflect the return you would realize if you actually owned shares of the underlying
stock and received the dividends paid or distributions made on them. |
| § | Reinvestment
risk. The term of your investment in the securities may be shortened due to the automatic
call feature of the securities. If the securities are automatically called prior to maturity,
you will receive no further payments on the securities and may be forced to invest in a lower
interest rate environment and may not be able to reinvest at comparable terms or returns.
However, under no circumstances will the securities be called at any point other than the
specified call settlement date. |
| § | The rate we are willing to pay for securities of this
type, maturity and issuance size is likely to be lower than the rate implied by our secondary market credit spreads and advantageous to
us. Both the lower rate and the inclusion of costs associated with issuing, selling, structuring and hedging the securities in the face
amount reduce the economic terms of the securities, cause the estimated value of the securities to be less than the face amount and will
adversely affect secondary market prices. Assuming no change in market conditions or any other relevant factors, the prices, if any,
at which dealers, including MS & Co., may be willing to purchase the securities in secondary market transactions will likely be significantly
lower than the face amount, because secondary market prices will exclude the issuing, selling, structuring and hedging-related costs that
are included in the face amount and borne by you and because the secondary market prices will reflect our secondary market credit spreads
and the bid-offer spread that any dealer would charge in a secondary market transaction of this type as well as other factors. |
The inclusion of the costs of issuing,
selling, structuring and hedging the securities in the face amount and the lower rate we are willing to pay as issuer make the economic
terms of the securities less favorable to you than they otherwise would be.
However, because the costs associated
with issuing, selling, structuring and hedging the securities are not fully deducted upon issuance, for a period of up to 3 months following
the issue date, to the extent that MS & Co. may buy or sell the securities in the secondary market, absent changes in market conditions,
including those related to the underlying stock, and to our secondary market credit spreads, it would do so based on values higher than
the estimated value, and we expect that those higher values will also be reflected in your brokerage account statements.
| § | The estimated value of the securities is determined by
reference to our pricing and valuation models, which may differ from those of other dealers and is not a maximum or minimum secondary
market price. These pricing and valuation models are proprietary and rely in part on subjective views of certain market inputs and
certain assumptions about future events, which may prove to be incorrect. As a result, because there is no market-standard way to value
these types of securities, our models may yield a higher estimated value of the securities than those generated by others, including other
dealers in the market, if they attempted to value the securities. In addition, the estimated value on the pricing date does not represent
a minimum or maximum price at which dealers, including MS & Co., would be willing to purchase your securities in the secondary market
(if any exists) at any time. The value of your securities at any time after the date of this document will vary based on many factors
that cannot be predicted with accuracy, including our creditworthiness and changes in market conditions. See also “The market price
will be influenced by many unpredictable factors” above. |
| § | The securities will not be listed on any securities exchange
and secondary trading may be limited. The securities will not be listed on any securities exchange. Therefore, there may be little
or no secondary market for the securities. MS & Co. and WFS may, but are not obligated to, make a market in the securities and, if
either of them once chooses to make a market, may cease doing so at any time. When they do make a market, they will generally do so for
transactions of routine secondary market size at prices based on their respective estimates of the current value of the securities, taking
into account their respective bid/offer spreads, our credit spreads, market volatility, the notional size of the proposed sale, the cost
of unwinding any related hedging positions, the time remaining to maturity and the likelihood that they will be able to resell the securities.
Even if there is a secondary market, it may not provide enough liquidity to allow you to trade or sell the securities easily. Since other
broker-dealers may not participate significantly in the secondary market for the securities, the price at which you may be able to trade
your securities is likely to depend on the price, if any, at which MS & Co. or WFS is willing to transact. If, at any time, MS &
Co. and WFS were to cease making a market in the securities, it is likely that there would be no secondary market for the securities.
Accordingly, you should be willing to hold your securities to maturity. |
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
| § | The calculation agent, which is a subsidiary of Morgan
Stanley and an affiliate of MSFL, will make determinations with respect to the securities. As calculation agent, MS & Co. will
determine the starting price, the threshold price, the ending price, whether the securities will be called on the call settlement date
and will calculate the amount of cash you receive at maturity, if any, if the securities are not automatically called prior to maturity.
Moreover, certain determinations made by MS & Co., in its capacity as calculation agent, may require it to exercise discretion and
make subjective judgments, such as with respect to the occurrence or non-occurrence of market disruption events and certain adjustments
to the adjustment factor. These potentially subjective determinations may adversely affect the payout to you at maturity. For further
information regarding these types of determinations, see “General Terms of the Securities—Certain Terms for Securities Linked
to an Underlying Stock—Market Disruption Events,” “—Adjustment Events,” “—Consequences of a
Market Disruption Event; Postponement of a Calculation Day,” “—Alternate Exchange Calculation in Case of an Event of
Default” and related definitions in the accompanying product supplement for principal at risk securities. In addition, MS &
Co. has determined the estimated value of the securities on the pricing date. |
| § | Hedging and trading activity by our affiliates could
potentially adversely affect the value of the securities. One or more of our affiliates and/or third-party dealers expect to carry
out hedging activities related to the securities (and possibly to other instruments linked to the underlying stock), including trading
in the underlying stock, as well as in other instruments related to the underlying stock. As a result, these entities may be unwinding
or adjusting hedge positions during the term of the securities, and the hedging strategy may involve greater and more frequent dynamic
adjustments to the hedge as the calculation day approaches. Some of our affiliates also trade the underlying stock and other financial
instruments related to the underlying stock on a regular basis as part of their general broker-dealer and other businesses. Any of these
hedging or trading activities on or prior to the pricing date could potentially affect the starting price, and, therefore, could increase
(i) the price at or above which the underlying stock must close on the call date so that the securities are automatically called for the
call payment and (ii) the threshold price for the underlying stock, which is the price at or above which the underlying stock must close
on the calculation day so that you do not suffer a loss on your initial investment in the securities. Additionally, such hedging or trading
activities during the term of the securities could potentially affect the price of the underlying stock on the call date, and, accordingly,
whether we call the securities prior to maturity and the amount of cash you will receive at maturity, if any. |
| § | The maturity date may be postponed if the calculation
day is postponed. If the scheduled calculation day is not a trading day or if a market disruption event occurs on that day so that
the calculation day is postponed and falls less than two business days prior to the maturity date, the maturity date of the securities
will be postponed to the second business day following that calculation day as postponed. |
| § | Potentially inconsistent research, opinions or recommendations
by Morgan Stanley, MSFL, WFS or our or their respective affiliates. Morgan Stanley, MSFL, WFS and our or their respective affiliates
may publish research from time to time on financial markets and other matters that may influence the value of the securities, or express
opinions or provide recommendations that are inconsistent with purchasing or holding the securities. Any research, opinions or recommendations
expressed by Morgan Stanley, MSFL, WFS or our or their respective affiliates may not be consistent with each other and may be modified
from time to time without notice. Investors should make their own independent investigation of the merits of investing in the securities
and the underlying stock to which the securities are linked. |
| § | The U.S. federal income tax consequences of an investment
in the securities are uncertain. Please read the discussion under “Additional Information About the Securities – Tax considerations”
in this document and the discussion under “United States Federal Taxation” in the accompanying product supplement for principal
at risk securities (together, the “Tax Disclosure Sections”) concerning the U.S. federal income tax consequences of an investment
in the securities. There is no direct legal authority regarding the proper U.S. federal tax treatment of the securities, and we do not
plan to request a ruling from the Internal Revenue Service (the “IRS”). Consequently, significant aspects of the tax treatment
of the securities are uncertain, and the IRS or a court might not agree with the tax treatment of a security as a single financial contract
that is an “open transaction” for U.S. federal income tax purposes. If the IRS were successful in asserting an alternative
treatment of the securities, the tax consequences of the ownership and disposition of the securities, including the timing and character
of income recognized by U.S. Holders and the withholding tax consequences to Non-U.S. Holders, might be materially and adversely affected.
Moreover, future legislation, Treasury regulations or IRS guidance could adversely affect the U.S. federal tax treatment of the securities,
possibly retroactively. |
Both U.S. and Non-U.S. Holders should
consult their tax advisers regarding the U.S. federal income tax consequences of an investment in the securities, including possible alternative
treatments, as well as any tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.
Risks Relating to the Underlying Stock
| § | No affiliation with Eli Lilly and Company. Eli Lilly
and Company is not an affiliate of ours, is not involved with this offering in any way, and has no obligation to consider your interests
in taking any corporate actions that might affect the value of the securities. We have not made any due diligence inquiry with respect
to Eli Lilly and Company in connection with this offering. |
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
| § | We may engage in business with or involving Eli Lilly
and Company without regard to your interests. We or our affiliates may presently or from time to time engage in business with Eli
Lilly and Company without regard to your interests and thus may acquire non-public information about Eli Lilly and Company. Neither we
nor any of our affiliates undertakes to disclose any such information to you. In addition, we or our affiliates from time to time have
published and in the future may publish research reports with respect to Eli Lilly and Company, which may or may not recommend that investors
buy or hold the underlying stock. |
| § | The antidilution adjustments the calculation agent is
required to make do not cover every corporate event that could affect the underlying stock. MS & Co., as calculation agent, will
adjust the adjustment factor for certain corporate events affecting the underlying stock, such as stock splits, stock dividends and extraordinary
dividends, and certain other corporate actions involving the issuer of the underlying stock, such as mergers. However, the calculation
agent will not make an adjustment for every corporate event that can affect the underlying stock. For example, the calculation agent is
not required to make any adjustments if the issuer of the underlying stock or anyone else makes a partial tender or partial exchange offer
for the underlying stock, nor will adjustments be made following the calculation day. In addition, no adjustments will be made for regular
cash dividends, which are expected to reduce the price of the underlying stock by the amount of such dividends. If an event occurs that
does not require the calculation agent to adjust the adjustment factor, such as a regular cash dividend, the market price of the securities
and your return on the securities may be materially and adversely affected. For example, if the record date for a regular cash dividend
were to occur on or shortly before the calculation day, this may decrease the ending price of the underlying stock to be less than the
threshold price (resulting in a loss of a significant portion or all of your investment in the securities), materially and adversely affecting
your return. |
| § | Historical closing prices of the underlying stock should
not be taken as an indication of the future performance of the underlying stock during the term of the securities. No assurance can
be given as to the price of the underlying stock at any time, including on the calculation day, because historical closing prices of the
underlying stock do not provide an indication of future performance of the underlying stock. |
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
Eli
Lilly and Company Overview |
Eli Lilly and Company discovers, develops, manufactures and sells pharmaceutical
products for humans and animals. The underlying stock is registered under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”). Information provided to or filed with the Securities and Exchange Commission by Eli Lilly and Company pursuant to the Exchange
Act can be located by reference to the Securities and Exchange Commission file number 001-06351 through the Securities and Exchange Commission’s
website at www.sec.gov. In addition, information regarding Eli Lilly and Company may be obtained from other sources including, but not
limited to, press releases, newspaper articles and other publicly disseminated documents. Neither the issuer nor the agent makes any
representation that such publicly available documents or any other publicly available information regarding the issuer of the underlying
stock is accurate or complete.
The following
graph sets forth the daily closing prices of the underlying stock for the period from January 1, 2019 through August 1, 2024. The closing
price of the underlying stock on August 1, 2024 was $832.44. We obtained the information in the graph below from Bloomberg Financial
Markets without independent verification. The historical closing prices of the underlying stock may have been adjusted for stock splits
and other corporate events. The historical performance of the underlying stock should not be taken as an indication of future performance,
and no assurance can be given as to the closing price of the underlying stock at any time, including on the call date or the calculation
day.
Common Stock of Eli Lilly
and Company – Daily Closing Prices
January 1, 2019 to August
1, 2024 |
|
This document relates only to the securities offered hereby and
does not relate to the underlying stock or other securities of Eli Lilly and Company. We have derived all disclosures contained in this
document regarding the underlying stock from the publicly available documents described above. In connection with the offering of the
securities, neither we nor the agent has participated in the preparation of such documents or made any due diligence inquiry with respect
to Eli Lilly and Company. Neither we nor the agent makes any representation that such publicly available documents or any other publicly
available information regarding Eli Lilly and Company is accurate or complete. Furthermore, we cannot give any assurance that all events
occurring prior to the date hereof (including events that would affect the accuracy or completeness of the publicly available documents
described above) that would affect the trading price of the underlying stock (and therefore the price of the underlying stock at the time
we price the securities) have been publicly disclosed. Subsequent disclosure of any such events or the disclosure of or failure to disclose
material future events concerning Eli Lilly and Company could affect the value received with respect to the securities and therefore the
value of the securities.
Neither the issuer nor any of its affiliates makes any representation
to you as to the performance of the underlying stock.
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
Additional
Information About the Securities |
Minimum ticketing size
$1,000 / 1 security
Tax considerations
Although there is uncertainty regarding the U.S.
federal income tax consequences of an investment in the securities due to the lack of governing authority, in the opinion of our counsel,
Davis Polk & Wardwell LLP, under current law, and based on current market conditions, it is reasonable to treat a security as a single
financial contract that is an “open transaction” for U.S. federal income tax purposes. However, because our counsel’s
opinion is based in part on market conditions as of the date of this document, it is subject to confirmation on the pricing date.
Assuming this treatment of the securities is respected
and subject to the discussion in “United States Federal Taxation” in the accompanying product supplement for principal at
risk securities, the following U.S. federal income tax consequences should result based on current law:
| § | A U.S. Holder should not be required to recognize taxable income over the term of the securities prior to settlement, other than pursuant
to a sale or exchange. |
| § | Upon sale, exchange or settlement of the securities, a U.S. Holder should recognize gain or loss equal to the difference between the
amount realized and the U.S. Holder’s tax basis in the securities. Such gain or loss should be long-term capital gain or loss if
the investor has held the securities for more than one year, and short-term capital gain or loss otherwise. |
We do not plan to request a ruling from
the Internal Revenue Service (the “IRS”) regarding the treatment of the securities. An alternative characterization of the
securities could materially and adversely affect the tax consequences of ownership and disposition of the securities, including the timing
and character of income recognized. In addition, the U.S. Treasury Department and the IRS have requested comments on various issues regarding
the U.S. federal income tax treatment of “prepaid forward contracts” and similar financial instruments and have indicated
that such transactions may be the subject of future regulations or other guidance. Furthermore, members of Congress have proposed legislative
changes to the tax treatment of derivative contracts. Any legislation, Treasury regulations or other guidance promulgated after consideration
of these issues could materially and adversely affect the tax consequences of an investment in the securities, possibly with retroactive
effect.
As discussed in the accompanying product
supplement for principal at risk securities, Section 871(m) of the Internal Revenue Code of 1986, as amended, and Treasury regulations
promulgated thereunder (“Section 871(m)”) generally impose a 30% (or a lower applicable treaty rate) withholding tax on dividend
equivalents paid or deemed paid to Non-U.S. Holders with respect to certain financial instruments linked to U.S. equities or indices that
include U.S. equities (each, an “Underlying Security”). Subject to certain exceptions, Section 871(m) generally applies to
securities that substantially replicate the economic performance of one or more Underlying Securities, as determined based on tests set
forth in the applicable Treasury regulations (a “Specified Security”). However, pursuant to an IRS notice, Section 871(m)
will not apply to securities issued before January 1, 2027 that do not have a delta of one with respect to any Underlying Security. Based
on the terms of the securities and current market conditions, we expect that the securities will not have a delta of one with respect
to any Underlying Security on the pricing date. However, we will provide an updated determination in the pricing supplement. Assuming
that the securities do not have a delta of one with respect to any Underlying Security, our counsel is of the opinion that the securities
should not be Specified Securities and, therefore, should not be subject to Section 871(m).
Our determination is not binding on
the IRS, and the IRS may disagree with this determination. Section 871(m) is complex and its application may depend on your particular
circumstances, including whether you enter into other transactions with respect to an Underlying Security. If withholding is required,
we will not be required to pay any additional amounts with respect to the amounts so withheld. You should consult your tax adviser regarding
the potential application of Section 871(m) to the securities.
Both U.S. and non-U.S. investors
considering an investment in the securities should read the discussion under “Risk Factors” in this document and the discussion
under “United States Federal Taxation” in the accompanying product supplement for principal at risk securities and consult
their tax advisers regarding all aspects of the U.S. federal income tax consequences of an investment in the securities, including possible
alternative treatments, and any tax consequences arising under the laws of any state, local or non-U.S. taxing jurisdiction.
The discussion in the preceding paragraphs under “Tax considerations”
and the discussion contained in the section entitled “United States Federal Taxation” in the accompanying product supplement
for principal at risk securities, insofar as they purport to describe provisions of U.S. federal income tax laws or legal conclusions
with respect thereto, constitute the full opinion of Davis Polk & Wardwell LLP regarding the material U.S. federal tax consequences
of an investment in the securities.
Additional considerations
Client accounts over which Morgan Stanley, Morgan Stanley Wealth Management
or any of their respective subsidiaries have investment discretion are not permitted to purchase the securities, either directly or indirectly.
Morgan Stanley Finance LLC
Market Linked Securities — Auto-Callable with Leveraged Upside Participation and Contingent Downside
Principal at Risk Securities Linked to the Common Stock of Eli Lilly and Company due August 19, 2027
Supplemental information regarding plan of distribution;
conflicts of interest
MS & Co. and WFS will act as the agents for this offering. WFS
will receive a commission of up to $25.75 for each security it sells. WFS proposes to offer the securities in part directly to the public
at the price to public set forth on the cover page of this document and in part to Wells Fargo Advisors (“WFA”) (the trade
name of the retail brokerage business of WFS’s affiliates, Wells Fargo Clearing Services, LLC and Wells Fargo Advisors Financial
Network, LLC), an affiliate of WFS, or other securities dealers at such price less a selling concession of up to $20.00 per security.
In addition to the selling concession allowed to WFA, WFS may pay $0.75 per security of the commission to WFA as a distribution expense
fee for each security sold by WFA.
In addition, in respect of certain securities sold in this offering,
we may pay a fee of up to $2.50 per security to selected securities dealers in consideration for marketing and other services in connection
with the distribution of the securities to other securities dealers.
See “Plan of Distribution; Conflicts of Interest”
in the accompanying product supplement for principal at risk securities for information about the distribution arrangements for the securities.
References therein to “agent” refer to each of MS & Co. and WFS, as agents for this offering, except that references to
“agent” in the context of offers to certain Morgan Stanley dealers and compliance with FINRA Rule 5121 do not apply to WFS.
MS & Co., WFS or their affiliates may enter into hedging transactions with us in connection with this offering.
MS & Co. is an affiliate of MSFL and a wholly owned subsidiary
of Morgan Stanley, and it and other affiliates of ours expect to make a profit by selling, structuring and, when applicable, hedging the
securities. When MS & Co. prices this offering of securities, it will determine the economic terms of the securities such that for
each security the estimated value on the pricing date will be no lower than the minimum price described in “Estimated Value of the
Securities” beginning on page 4.
MS & Co. will conduct this offering in compliance with the requirements
of FINRA Rule 5121 of the Financial Industry Regulatory Authority, Inc., which is commonly referred to as FINRA, regarding a FINRA member
firm’s distribution of the securities of an affiliate and related conflicts of interest. MS & Co. or any of our other affiliates
may not make sales in this offering to any discretionary account. See “Plan of Distribution (Conflicts of Interest)” and “Use
of Proceeds and Hedging” in the accompanying product supplement.
Where you can find more information
Morgan Stanley and MSFL have filed a registration statement (including
a prospectus, as supplemented by the product supplement for principal at risk securities) with the Securities and Exchange Commission,
or SEC, for the offering to which this communication relates. You should read the prospectus in that registration statement, the product
supplement for principal at risk securities and any other documents relating to this offering that Morgan Stanley and MSFL have filed
with the SEC for more complete information about Morgan Stanley, MSFL and this offering. When you read the accompanying product supplement,
please note that all references in such supplement to the prospectus dated November 16, 2023, or to any sections therein, should refer
instead to the accompanying prospectus dated April 12, 2024 or to the corresponding sections of such prospectus, as applicable. You may
get these documents without cost by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, Morgan Stanley, MSFL, any underwriter
or any dealer participating in the offering will arrange to send you the product supplement for principal at risk securities and prospectus
if you so request by calling toll-free 1-(800)-584-6837.
You may access these documents on the SEC web site at www.sec.gov as
follows:
Product
Supplement for Principal at Risk Securities dated November 16, 2023
Prospectus
dated April 12, 2024
Terms used but not defined in this document are defined in the product
supplement for principal at risk securities or in the prospectus.
Morgan Stanley (NYSE:MS-P)
過去 株価チャート
から 9 2024 まで 10 2024
Morgan Stanley (NYSE:MS-P)
過去 株価チャート
から 10 2023 まで 10 2024